Κλαύδιος Γαληνός
Δωρεάν εγγραφή Αποκτήσετε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr για έναν μήνα
Γαληνός Office Χρησιμοποιήστε δωρεάν το νέο cloud πρόγραμμα διαχείρισης κάθε σύγχρονου ιατρείου
Έλεγχος συγχορήγησης Ελέγξτε την αγωγή σας για αντενδείξεις και αλληλεπιδράσεις μεταξύ των φαρμάκων
Μητρότητα και φάρμακα Ενημερωθείτε για την ασφάλεια χορήγησης ενός φαρμάκου κατά τη διάρκεια της εγκυμοσύνης ή του θηλασμού
Πρόγραμμα συνδρομητών Μάθετε περισσότερα για τα οφέλη και τις επιπλέον παροχές των συνδρομητικών προγραμμάτων
Γαληνός Mobile Κατεβάστε τη δωρεάν εφαρμογή και απολαύστε τις υπηρεσίες του Galinos.gr σε κινητό ή tablet
Γνωρίζατε οτι... Μοιραζόμαστε μαζί σας γεγονότα της πορείας του Galinos.gr από το 2011 μέχρι σήμερα
®
 Φάρμακα Α - Ζ  Συγχορήγηση  Μητρότητα

FIBROGAMMIN Powder and solvent for solution for injection (2018)

Αναφορές

Βιβλιογραφική αναφορά

Για την προβολή της πλήρους καταχώρησης απαιτείται συνδρομή σε ισχύ.
Αποκτήστε πρόσβαση σε όλες τις πληροφορίες και τα εργαλεία του Galinos.gr δωρεάν για έναν μήνα απλά κάνοντας εγγραφή.
Δωρεάν εγγραφή

Περιεχόμενα

Name of the medicinal product

Fibrogammin 250/1250 IU. Powder and solvent for solution for injection or infusion.

Qualitative and quantitative composition

Active substance: Fibrogammin is a purified concentrate of blood coagulation factor XIII (FXIII). It is derived from human plasma and is presented as a white powder. Each vial contains nominally 250 or ...

Pharmaceutical form

Powder and solvent for solution for injection/infusion. White powder and clear, colourless solvent.

Therapeutic indications

Fibrogammin is indicated for adult and paediatric patients. Congenital deficiency of Factor XIII and resultant haemorrhagic diathesis, haemorrhages and disturbances in wound healing.

Posology and method of administration

Posology 1 ml is equivalent to 62.5 IU, and 100 IU are equivalent to 1.6 ml, respectively. Important: The amount to be administered and the frequency of administration should always be orientated towards ...

Contraindications

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Special warnings and precautions for use

In patients with known allergies to the product, with symptoms such as generalised urticaria, rash, a fall in blood pressure, dyspnoea, antihistamines and corticosteroids may be administered prophylactically. ...

Interaction with other medicinal products and other forms of interaction

No interaction studies have been performed.

Fertility, pregnancy and lactation

Pregnancy Limited data on the clinical use of Fibrogammin in pregnancy did not show any negative effects on the course of gestation and the peri- or postnatal development. The use of Fibrogammin may be ...

Effects on ability to drive and use machines

No studies on the effects on the ability to drive and use machines have been performed.

Undesirable effects

The following adverse reactions are based on post-marketing experience. Tabulated list of adverse reactions The table presented below is according to the MedDRA system organ classification. Frequencies ...

Overdose

No cases of overdose have been reported.

Pharmacodynamic properties

Pharmacotherapeutic group: Antihaemorrhagics ATC code: B02BD07 Biochemically, factor XIII acts as transglutaminase. Factor XIII connects the amino group of lysine with glutamine via its enzymatic function ...

Pharmacokinetic properties

Distribution The product is administered intravenously, and is thus immediately bioavailable resulting in a plasma concentration corresponding to the applied dose. Elimination In patients with congenital ...

Preclinical safety data

The proteins contained in Fibrogammin are sourced from human plasma and act like human plasma proteins. Single and repeated dose toxicity studies in animals did not reveal a toxic potential for Fibrogammin. ...

List of excipients

Powder: Human albumin Glucose monohydrate Sodium chloride* Sodium hydroxide (for pH adjustment) * see also section 4.4 Solvent: Water for Injections

Incompatibilities

Fibrogammin must not be mixed with other medicinal products, diluents, or solvents except those mentioned in section 6.6 and should be administered by a separate infusion line.

Shelf life

Shelf life: 3 years. Do not use after the expiry date given on the pack and container. Do not freeze reconstituted solution. Chemical and physical in-use stability has been demonstrated for 24 hours at ...

Special precautions for storage

Store in a refrigerator (+2 to +8 °C). Do not freeze. Keep the vial in the outer carton in order to protect from light. For storage conditions after reconstitution of the medicinal product, see section ...

Nature and contents of container

Vials 250 IU: Powder: injection vial of colourless glass, sealed with a bromobutyl rubber stopper, aluminium cap and plastic disc. Solvent (Water for Injections): vial of colourless glass 1250 IU: Powder: ...

Special precautions for disposal and other handling

General instructions The solution should be clear or slightly opalescent. After filtering/withdrawal (see below) the reconstituted product should be inspected visually for particulate matter and discoloration ...

Marketing authorization holder

CSL Behring GmbH, Emil-von-Behring-Strasse 76, 35041, Marburg, Germany

Marketing authorization number(s)

PL 15036/0006

Date of first authorization / renewal of the authorization

22 June 1998 / 30 October 2003

Date of revision of the text

16 July 2018

Πηγαίο έγγραφο

Το πηγαίο έγγραφο για αυτήν την βιβλιογραφική αναφορά είναι διαθέσιμο προς μεταφόρτωση: